Immunovant, Inc. last reported quarterly results on Aug 6, 2026, for Q1 FY2027 (the quarter ended Jun 30, 2026): diluted EPS of -$0.75. It usually reports 37–50 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 9, 2026.
Results for Q2 FY2027, the quarter ending around Sep 30, 2026. Expected on a Monday. Based on last year's release for the same quarter on Nov 10, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–50 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 6, 2026
37 days after quarter end
|
Q1 FY2027
ended Jun 30, 2026
|
—
|
-153
-27.0%
|
-0.75
-5.6%
|
|
May 20, 2026
50 days after quarter end
|
Q4 FY2026
ended Mar 31, 2026
|
—
|
-148
-38.9%
|
-0.73
-13.7%
|
|
Feb 6, 2026
37 days after quarter end
|
Q3 FY2026
ended Dec 31, 2025
|
—
|
-111
+0.4%
|
-0.61
+19.7%
|
|
Nov 10, 2025
41 days after quarter end
|
Q2 FY2026
ended Sep 30, 2025
|
—
|
-127
-15.9%
|
-0.73
+1.4%
|
|
Aug 11, 2025
42 days after quarter end
|
Q1 FY2026
ended Jun 30, 2025
|
—
|
-121
-38.4%
|
-0.71
-18.3%
|
|
May 29, 2025
59 days after quarter end
|
Q4 FY2025
ended Mar 31, 2025
|
—
|
-106
-41.3%
|
-0.64
-23.4%
|
|
Feb 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Dec 31, 2024
|
—
|
-111
-116.1%
|
-0.76
-111.1%
|
|
Nov 7, 2024
38 days after quarter end
|
Q2 FY2025
ended Sep 30, 2024
|
—
|
-109
-86.0%
|
-0.74
-64.4%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IMVT (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1764013
- Former names
- Health Sciences Acquisitions Corp (until Dec 20, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.